Abstract Number: 119 • 2019 ACR/ARP Annual Meeting
Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model
Background/Purpose: Polymyositis is a chronic inflammatory myopathy associated with lymphocyte infiltration, especially CD8 + T cells to the muscle layer. C protein-induced myositis (CIM) is a murine…Abstract Number: 120 • 2019 ACR/ARP Annual Meeting
Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Background/Purpose: Autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to…Abstract Number: 121 • 2019 ACR/ARP Annual Meeting
In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition
Background/Purpose: Animal models of experimental spondyloarthritis (SpA), human genetics and therapies support a central role for adaptive immunity in disease pathogenesis. However, there is very…Abstract Number: 122 • 2019 ACR/ARP Annual Meeting
Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis
Background/Purpose: In polymyositis (PM), CD8+ cytotoxic T lymphocytes (CTLs) are assumed to induce muscle cell death. We presumed that the injured muscle cells release pro-inflammatory…Abstract Number: 123 • 2019 ACR/ARP Annual Meeting
Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
Background/Purpose: The activation of T helper cells requires cognate recognition of antigen-derived peptides presented by Major Compatibility Complex Class II (MHC II) molecules, which are…Abstract Number: 124 • 2019 ACR/ARP Annual Meeting
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Background/Purpose: Circulating CD4 T cells that express CXCR5 together with PD-1 and/or ICOS are considered as counterparts of bona fide Tfh cells and function as…Abstract Number: 125 • 2019 ACR/ARP Annual Meeting
Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most frequent form of systemic vasculitis affecting the large- and medium-sized vessels. The involvement of innate immune cells…Abstract Number: 126 • 2019 ACR/ARP Annual Meeting
Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS
Background/Purpose: Mitochondria are intracellular organelles involved in many biological pathways such as energy supply by oxidative phosphorylation and apoptosis. Mitochondria are considered as derived from…Abstract Number: 127 • 2019 ACR/ARP Annual Meeting
Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome
Background/Purpose: The leukocyte immunoglobulin-like receptor A3 (LILRA3) gene encodes the only soluble receptor within the LILR family. LILRA3 polymorphisms have been associated with both rheumatoid…Abstract Number: 128 • 2019 ACR/ARP Annual Meeting
Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis
Background/Purpose: The metabolic disturbances that underlie antiphospholipid syndrome (APS) are currently unknown. The goal of this study was to utilize high-throughput metabolomics screening to identify…Abstract Number: 129 • 2019 ACR/ARP Annual Meeting
Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboses and/or obstetric complications in presence of antiphospholipid antibodies (aPL). Extracellular vesicles have been suggested to play a…Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…Abstract Number: 131 • 2019 ACR/ARP Annual Meeting
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC. Some have suggested a clinically useful role for aPS-PT as a…Abstract Number: 132 • 2019 ACR/ARP Annual Meeting
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with…Abstract Number: 133 • 2019 ACR/ARP Annual Meeting
Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Background/Purpose: Anti-β2GPI-Domain 1 (β2GPI -D1) antibodies are currently considered to be a pathogenic subset of anti-β2GPI antibodies and have been strongly associated with thrombosis and…
ACR Meeting Abstracts